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Evidence Based Cross Validation for Acoustic Power Transmission via 
Trans-Fusimo Treatment System Software for MR Guided Focused 
Ultrasound  
2) Abstract 
Introduction The novel Trans-Fusimo Treatment System (TTS) is designed to control Magnetic 
Resonance guided Focused Ultrasound (MRgFUS) therapy to ablate liver tumours under 
respiratory motion.  It is crucial to deliver the acoustic power within tolerance limits for effective 
liver tumour treatment via MRgFUS.  Before application in a clinical setting; evidence of 
reproducibility and reliability is a must for safe practice.  Materials and methods The TTS 
software delivers the acoustic power via ExAblate-2100 Conformal Bone System (CBS) 
transducer.  A built-in quality assurance application was developed to measure the force values, 
using a novel protocol to measure the efficiency for the electrical power values of 100 and 150W 
for 6s of sonication.  This procedure was repeated thirty times by two independent users against 
the clinically approved ExAblate-2100 CBS for cross-validation.  Results Both systems proved 
to deliver the power within the accepted efficiency levels (70-90%).  Two sample t-tests were 
used to assess the differences in force values between the ExAblate-2100 CBS and the TTS 
(p>0.05).  Bland-Altman plots were used to demonstrate the limits of agreement between the two 
systems falling within the 10% limits of agreement.  Two sample t-tests indicated that TTS does 
not have user dependency (p>0.05).  Conclusions The TTS software proved to deliver the 
acoustic power without exceeding the safety levels.  Results provide evidence as a part of 
ISO13485 regulations for CE marking purposes.  The developed methodology could be utilised 
as a part of quality assurance system in clinical settings; when the TTS is used in clinical 
practice. 
3) Keywords: acoustic power measurement for reliability; Blant-Altman; cross-
validation; quality assurance; legislation; pre-clinical MRgFUS, two-sample t-
test. 
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4) Main text 
a) Introduction 
   Magnetic Resonance guided Focused Ultrasound (MRgFUS) has been CE 
Conformité Européene), and Food & Drug Administration (FDA) approved for the 
treatment of uterine fibroids and the treatment of pain for bone metastasis [1-4]. ExAblate 
2000 and 2100 (InSightec, Israel) are systems for treatment of these diseases, to apply the 
static MRgFUS technique.  However, the targeting of Focused Ultrasound (FUS) in upper 
abdominal organs, such as in liver remains particularly challenging due to the complexity 
of the displacement and the deformation due to the respiratory motion; adjacent risk 
structures and the possible interference by the rib cage [5].  Trans-Fusimo Treatment 
System (TTS) software (FP7 Project Trans-Fusimo, Fraunhofer, Mevis, Germany) is a 
recently developed software aiming at treatment of liver by using MRgFUS methodology.  
This novel software makes use of the mathematical models describing the motion due to 
breathing, the propagation of the ultrasound waves through the rib cage, and into the 
targeted tumour destination and the multi-base line algorithm to read the temperature 
during ablation [5].  Virtual reality simulations prove to be promising in achieving an 
accurate prediction of a real patient scenario [5].  However, safe and efficient application 
of this procedure requires and depends on successful configuration of the hardware and 
the efficient transmission of electrical power being converted into acoustical power.  
 
The TTS system drives the transducer of the Conformal Bone System (CBS) (InSightec, 
Ltd, Tirat Carmel, Israel).  To achieve this task, TTS software has a Graphical User 
Interface (GUI) where an operator activates a command to drive the transducer.  GUI 
requires an operator to provide the information for the planned sonication coordinates, 
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sonication power, and the duration.  An electronically steerable FUS transducer receiving 
this sonication command has a grid of small transducer elements.  Focusing the 
transducer to a position is achieved by altering the phase differences between the 
elements such that the single element waves superpose constructively in the intended 
focal spot.  During sonication in MR imaging, the phase values of the sonicated spot 
change.  Based on this change, the colour mapped thermometry data reflecting the 
temperature increase caused by the FUS ablation, is visualized in the user interface of the 
TTS software.  These images are collected by using the 1.5 T MR Scanner (GE 
Healthcare, UK) and sent to the TTS software in real time.  The system configuration is 
shown in detail on Figure1.  The treatment system requires real time interaction of sub-
systems (Figure1) such as TTS workstation; TTS software; InSightec Control PC and 
CBS transducer; MR work station and Scanner.  A Transistor-Transistor-Logic (TTL) 
pulse generator provides synchronization with TTS software and the MR Scanner.  
[Insert Fig1]  
The TTS software is classified as class 3/C high risk software, where serious injury or 
death is possible according to the international standard IEC 62304.  It requires deep 
design documentation and testing before clinical trials.  The TTS software controls the 
FUS transducer by sending the newly computed phase information to the FUS transducer 
to ablate human tissue; therefore, the major risk is that the TTS software might send the 
wrong command to the FUS transducer which may produce unexpected levels of power.  
Having this complex infrastructure, it is crucial to develop reliable protocols following 
the requirements of International Organisation for Standardization ISO 13485 Quality 
Management System (QMS).  This is a mandatory step for CE mark approval for clinical 
use.  The CE mark is a legal designation that a medical product has met the requirements 
of all relevant Medical Device Directives in the EU.  In this study, the power protocol, 
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which was developed according to the requirements of ISO 13485, is explained in detail.  
ISO13485 provides the standards for evaluation of complex systems by taking 
precautions to prevent any errors and traps in the planning stage.  An important part of 
the quality control is the detection of both random and systematic errors.  This is achieved 
by critically looking at the performance, the analyses; the instruments and the operators 
taking part in the evaluation [6]. For this reason, design and development plans, risk 
assessment forms, risk assessment matrices and traceability matrices for the designed 
protocol is prepared according to the rules and regulations of ISO13485. To eliminate 
risk related to false positive and false negative test results, special attention was given to 
prepare easy to follow protocols; measuring one process parameter at a time only.  The 
developed protocol enables the collection of results for the delivered acoustic power 
during a FUS application, and is utilised as a part of the required evidence for getting 
approvals for safe use in clinics.  However, the TTS does not only require development 
of the power protocol but also the development of protocols for measuring the sonication 
duration; the position and thermometry to provide quantitative evidence in pre-clinical 
settings [7].  For this reason, initially, the system parameters were identified for the full 
system validation and the specs for these parameters were determined based on the 
current lab practices for static and moving case applications [7].  Based on the successful 
evaluation of the static and the moving case scenario validations of the TTS in pre-clinical 
settings, more clinical evidence via animal testing is intended to be collected [7].  Finally, 
the evidence of successful application of the treatment on volunteered patients, leads into 
the successful approval of CE marking procedure for MRgFUS in clinical settings. 
 
The US Food and Drug Administration (FDA) has also reported requirements that the 
equipment should not be used for clinical application if it generates higher acoustic power 
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levels than similar equipment produced for the same application [6].  Power over a certain 
level might lead into skin burns of the patients and self-heating of the transducer [6].  In 
analytical work, data and its comparison against established standard is very important.  
In this study, the acoustic power data is used as an indication of performance so that it 
can provide guidance on safety.  Knowledge of the output allows relative risk assessments 
of different values of power.  Knowing the output of the acoustic power can help provide 
evidence for safe usage.  
 
Measurement traceability is an important concept.  To ensure that the comparisons 
between measurements made by different laboratories are valid, there is a need for 
common standard and concept [8].  For this reason, in this paper the FDA approved 
ExAblate 2100 CBS is treated as a gold standard when validating the recently developed 
TTS.  Qualitative methods play an important role in performance assessment of the 
acoustic power.  One of the reasons for using the qualitative methodology is to ensure 
that the most effective exposure levels are used during patient treatment.  Another reason 
is to ensure that the exposure does not take place at levels which can be harmful to the 
human tissue [7].  It is also useful to know if the equipment is performing satisfactorily.  
Power is a useful and simple parameter for periodic performance evaluation [8].  In this 
study, the acceptable level for efficiency for converting electrical power to acoustic power 
is defined as 70-90%. 
 
There have been several measurement methodologies in the literature for measuring the 
acoustic power output [6, 8-15].  One of them is the large target radiation force 
methodology [6], where the target intercepts the whole ultrasonic beam to indicate a value 
of the total acoustic power.  The principle in the radiation force methodology is that 
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propagation of ultrasound through a medium is related to the transfer of momentum.  This 
transfer shows itself as a force acting on the targeted area. Measurement of this force 
provides the base value for power.  The force actually depends on the time-averaged 
intensity in the ultrasonic beam.  In this study, large target methodology is used where 
the target intercepts the whole of the ultrasonic beam to yield the total value of the 
acoustic power.  The force is related to the acoustic power, W, as described by the 
following                                expression: 
F=h.W/c                                                                                                                          (1) 
 
Where c is the speed of ultrasound in the propagating medium (in our case water), h is a 
parameter that depends on the geometry of the target and is equal to 1 for plane or totally 
absorbing target [6].  Large target radiation force balance is classified as ideal for low 
cost and ease of use [6] and preferred in this study due to these advantages.  Acoustic 
power measurements were completed by following the described protocol in this study.  
To cross validate the TTS software, against the clinical MRgFUS system, ExAblate 2100 
CBS, by two independent operators on the same set up; to observe the limits of agreement 
and the differences between the means of the measured power values, and the user 
dependency of both systems to provide evidence to fulfil the requirements of 
implementation of ISO 13845.  
b) Methodology  
The protocol developed to test the ExAblate 2100 CBS system for obtaining FDA 
approval, was used with TTS software.  A feasibility study was performed initially to 
verify the usage of the same protocol for applying electric power values of 100 W and 
150 W for 6 seconds of sonication.  These values are chosen to evaluate proper dosimetry 
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of the system with the actual acoustic power output by applying the protocol conforming 
to the requirements of ISO 13485 at our laboratory. 
Preparation  
Radiation force is measured by the weight scale holder assembly (InSightec Ltd, Tirat 
Carmel, Israel) (Figure2a).  Radiation force is detected by CM 150-1 Weight Scale. This 
scale is placed on the target in the FUS beam direction of the CBS transducer, parallel to 
the transducer.  Prior to the experiment, the initial force reading was completed by using 
a known weight on CM 150-1 Weight Scale for calibration purposes with an accuracy of 
0.1 g.  
[Insert Fig2a-f] 
The force detected by the weight scale is directly proportional to the ultrasonic power 
providing the whole beam is intercepted (Eq1) [7]. Eq1 assumes that plane waves are 
incident on the target for fields generated by plane transducers.  The main equipment used 
in this stage is a fixed transducer (CBS, 1024 elements) and as a non-fixed target; the 
force balance platform, is used in this study (Figure2a).  To determine the total acoustic 
power output of a transducer, it is essential that the target is of sufficient size to intercept 
the whole of the ultrasonic beam.  In this study, both the CBS transducer and the target 
have equal diameters.  The algorithm used by the TTS for calculating the phases is shown 
below (pseudo code), with the assumption of homogeneous medium. 
 
K = 2.0 * pi * Frequency / SpeedOfSound; 
for (elementIndex = 0 .. numberOfElements) { 
   Phase[elementIndex] = K * DistanceToElement(elementIndex, focusPosition); 
  
} 
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The power value entered in the graphical user interface during planning is used for the 
“Regular Sonication Electric Power” parameter.  
With C=1500 [m/sec] and the equivalence of 102 gram/N, to calculate power the equation 
below is used (Eq2).  
 
P [Watt] = 14.7*F[gram]                                                           (2) 
Where P was the absorbed power in target (Watt), and F was the exerted force on target 
[N]. 
Trans-Fusimo Execute Sonication Application  
 
For regular quality assurance (QA) purposes, the TTS software has a Trans-Fusimo 
Execute Sonication Application (TESA).  The main TTS software requires time 
consuming treatment planning imaging, and monitoring of the sonication procedure for 
thermometry data and tracking of land marks.  However, TESA does not require MR 
monitoring and imaging.  This protocol enables the power measurement procedure in a 
realistic time frame for the planned number of sonications to take place by two 
independent operators without providing any imaging or thermometry information but 
power information only. 
 
To use TESA, the information for the magnitude of electrical power, the focal position, 
and the duration of sonication is entered manually by the operator into the graphical user 
interface (GUI), as shown in Figure3a.  Pressing the “Arm HIFU Transducer” button 
initializes the transducer and makes it ready for instant sonication i.e. the transducer is 
powered up and the elements are configured to random phases and almost-zero output 
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power.  Once arming is complete, the sonication can be executed.  Pressing the “Execute 
Sonication” button configures the transducer to focus on the specified position with the 
specified power.  The sonication duration is completed by running a loop of 250-ms 
sonication intervals (due to safety reasons) until the planned duration time is reached.  
Once this loop is complete, sonication is stopped automatically.  The “Stop Sonication” 
button is not activated in this protocol by the operator it is used only when there is an 
emergency. 
 [Insert Fig3 a b] 
Test Protocol  
A qualified operator secures cable connections for the TTS software to control the 
transducer (Figure 1).  The Control PC rack of ExAblate 2100 (InSightec, Israel) is put 
on power for CBS transducer.  A phantom holder is placed over the transducer (Figure 
2b).  To provide good acoustic coupling, the membrane is supposed to be kept wet.  For 
this reason, wet tissue is placed between the membrane and the phantom holder.  The 
phantom holder is filled with degassed water 3 cm below of the top of the cylinder.  Wet 
tissue is removed (Figure 2c).  The cooling system of the CBS transducer is put in 
circulation mode at least for 10 minutes.  Verification is then performed to check if there 
are any air bubbles between the membrane and phantom holder by visual inspection and 
MR scanning in sagittal, coronal and axial views. If any air bubbles are present; the 
operator will remove them for safe usage of the system.  After corrective actions are 
taken, another MR scan is completed to double check if there are any remaining air 
bubbles.  The distance from the setup base to the phantom holder bottom is measured and 
recorded.  This ensures the same membrane inflation each time for reproducibility 
purposes. 
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The weight scale holder assembly is shown in a sketch (Figure 2g). This assembly is 
placed in the cylinder and inserted diagonally to prevent trapping of air bubbles (Figure 
2c); the holder is then checked for levelness.  There is a tolerance between holder legs 
and holes in the disk to rest on the water bath (Figure 2d).  The scales are placed between 
the absorbing target and the freely moving legs to measure the force as shown in Figure 
2e.  The triangular platform is free to move along the beam direction so that force values 
can be read from the scales and recorded (Figure 2f). 
Test Parameters  
To measure the acoustic power, a sonication is performed with the parameters described 
below by using the TESA graphical user interface, with the parameters in Table 1a. 
When sonication is applied, the weight is viewed on the weight scale screen.  When the 
reading on the balance stabilizes, the weight difference between the maximum value 
during the sonication and the value after the sonication ended is calculated in grams. The 
collected force data is recorded for each sonication.  Using Eq.2, the power is calculated.  
The efficiency is calculated by dividing the calculated power by input power.  The result 
is checked, if it is within the acceptable tolerance range (70 to 90%). The sonication is 
repeated for 30 times by two independent operators. The null hypothesis is that system is 
indifferent to different operators.  
Validation against Gold Standards 
CGA stands for Central GUI Application, installed on the Control PC (CPC) of the CBS 
ExAblate2100.  Using the same setup, the CGA software of the ExAblate 2100 System 
was activated (Figure 3b).  The GUI of the CGA allows to define the magnitude of 
electrical power, the focal position and the sonication duration.  The same test parameters 
were applied by two independent users for sonication for 30 times.  These features are 
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shown in Figure3b.  Both TESA and CGA have this manual input interface for the 
operators to provide input. 
Post Processing of the Data 
From the calculated power data for each system and operator, the average power was 
calculated.  Average efficiency was calculated by dividing average power by planned 
input power.  Mean values and standard deviations (SD) for each operator and each 
system were provided as indication of performance of the system.  The graphs showing 
the number of trials and calculated power value were plotted.  A trend line was fitted in 
to each plot to calculate the Normalized Root Mean Square Error (NRMSE).  NRMSE 
was calculated by dividing the RSME with the average magnitude of the measured data, 
to eliminate dependency on measured magnitude.  NRMSE was used as a measure of 
accuracy.  
To construct the B&A plot and to evaluate the agreement, each data set was measured by 
using the TTS and the ExAblate 2100 CBS and then sorted from smallest to largest and 
paired [15].  The difference for each paired data was calculated by simple subtraction 
(TTS data -ExAblate 2100 CBS data).  The mean for each paired data was calculated by 
adding each paired data and dividing by 2 (TTS data + ExAblate 2100 CBS data)/2.  B&A 
was plotted using the differences between two data sets against the mean of the two 
measurements.  Plotting difference against mean allows us to investigate any possible 
relationship between the measurement error and the true value [15].  The mean of the two 
paired measurements was assumed as the true value.  The percentile difference for each 
paired data was calculated by dividing the difference by the calculated mean 
Difference/Mean (%). The average of this percentile differences was calculated for the 
full data set to check against the previously set 10% difference criterion based on the 
current lab practices.  The limits of agreements between two systems were calculated by 
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using the mean value ± 2s (standard deviation). It is recommended that 95% of the data 
points should lie within the ± 2s of the mean difference as demonstrated in B&A plots 
[15]. 
 
Two sample t-tests were used to investigate the significance of difference between the 
mean values of the delivered power by using the TTS and ExAblate 2100 CBS.  Two 
sample t-tests were also utilised to check the significance of difference based on two 
independent operators using the system. 
c) Results 
Descriptive statistics for calculated power and calculated average efficiency are listed for 
applied power of 100 W and 150 W for both TTS software and ExAblate 2100 systems 
in Table1b and Table 1c respectively for both operators.  The acoustic efficiency is 
calculated for each system.  Results show that both systems produce efficiency values 
within the accepted tolerance limits (70-90%).  There is no single data falling out of this 
efficiency range during the experiments for each system. 
 
The calculated acoustic power versus number of trials graphs are provided for each 
operator (Figure Appendix).  By using the fitted line as a model and computed acoustic 
power as the data, the NRMSE was calculated for each data set.  For the first operator 
with TTS software NRMSE for 100 W and 150W was calculated as 0.02 and 0.04 
respectively.  For the second operator, NRMSE was 0.02 and 0.01 respectively and for 
ExAblate2100, NRMSE was calculated as 0.02 and 0.01 for the first operator and 0.02 
and 0.01 respectively.  Overall, NRMSE being less than 0.1 for both systems indicated 
good accuracy levels. 
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The calculated mean difference (%) between the TTS and the ExAblate 2100 was 0,13 
% for 100 W and 3.8 % for 150 W, meeting the pre-defined spec based on current lab 
practices, which was set as 10 %.  Bland-Altman plots were used to interpret the limits 
of agreement.  Any other new set of tests by using the TTS software and ExAblate 2100 
would be expected to fall in the limits of agreement shown in the graphs (Figure 4 a-d) 
with 95% level of confidence.  Two-sample t-tests were used to assess the differences in 
force values between the ExAblate-2100 CBS and the TTS (p>0.05), indicating the 
difference between the means is insignificant. 
 
Two-sample t-tests were also used to assess the dependency of the system to the 
operators.  P values were calculated for 100W and 150W between the operators for using 
TTS.  P being >0.05, the null hypothesis is not rejected.  Also for ExAblate 2100, P values 
for delivered acoustic power values of 100 W and 150 W between the operators were 
calculated as (p>0.05).  The results show that there is no significant difference in 
delivered power, due to different operators for both systems. 
[Insert Table1a-c] 
[Insert Fig 4 a- d] 
d) Discussions 
 The Trans-Fusimo Treatment System software aims at sonicating to a moving target (i.e. 
liver tumour) by delivering high levels of power.  The radiation force technique is the 
most widely used and accepted fundamental technique due to its practicality [16]. For 
safe delivery of the power, it is crucial that the system is deemed to be reliable and to be 
producing acoustic power outputs [16] within the established safety margins in in a 
reproducible way. 
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To evaluate this, the developed protocol was used to compare against the approved 
systems standards.  Feasibility tests were run before the independent operators ran their 
sessions.  Prior to the experiments, risk assessment forms were filled in.  Risk assessment 
matrices were evaluated based on the severity of risk involved and probability of the risk 
occurring during the experiments.  Risk mitigation procedures were completed and 
traceability matrices were evaluated for each risk mitigation point. Risk mitigation points 
involved secure cabling between subsystems such as TTL cable from the TTS 
workstation, to MR scanner and ExAblate 2100 CBS, to avoid any power transmission 
problems, calibration of the scales, and training of the operators to understand the 
protocol steps in application. Instructions were printed before the repeatability 
experiments and operators followed the steps accordingly, so that the dependency of the 
system to operator’s usage was minimized.  T-test evaluations showed that the difference 
in acoustic power between the independent operators using the same system is 
insignificant with p>0.05.  One of the limitations of this study was that independent 
operators were not randomized and only two qualified operators tested the system.  
Although as an improvement point; it could be argued that the number of operators should 
be increased, with a p value being greater than 0.05, this would only lead into more testing 
time and results might not have been affected.  The results imply that the designed 
protocols were effective in guiding the operators to apply the protocols correctly. Ideally, 
the system is not expected to produce different power values when different operators 
employ it.  The results are also in support of this expectation. 
 
Statistical methods used to test for agreement of medical instruments, play a crucial role 
to draw correct conclusions from the data gathered to compare the devices.  Bland-Altman 
(B&A) plots are reported to be the most popular statistical method when testing for 
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agreement of medical instruments [18].  This method provides the means to check how 
close the pairs of values are from two different systems.  It also relaxes the expectation 
that two different instruments with different methodologies should give identical paired 
measurements.  The other option to evaluate consistency between the two systems would 
be the correlation coefficient (r).  However, the correlation coefficient is more suitable 
for investigating the linear relationship.  It is not our expectation that two systems should 
produce paired linearly increasing or decreasing values in this protocol.  The B&A plot 
analysis is a simple way to evaluate a bias between the mean differences, and to estimate 
an agreement interval, within which 95% of the differences of the second method, 
compared to the first one, fall [15].  The B&A plots define the intervals of agreements as 
shown in Figure 4 a-d.  The limits of agreement between the means were set as 10 % prior 
to the design of the experiments for checking the acceptable limits of agreement with 
B&A plots.  The plots show that all the measured data using TTS software and the gold 
standard used in this study, fall into the ±1.96+ mean difference interval, meeting the 
specifications set prior to the current experiments.  B&A methodology was considered as 
a suitable statistical method to draw conclusions based on the designed protocol.  To 
evaluate the significance of difference between the ExAblate 2100 CBS and the TTS, two 
sample t-tests showed that the difference between the means by ExAblate 2100 CBS and 
TTS is insignificant; p>0.05. 
 
Quantitative analysis of the results shows that the efficiency is relatively low (73%) for 
100 W, when compared to 150 W (80-83%).  This could be explained by the fact that h 
value in Eq1, is actually higher than unity for higher powers as it is difficult to produce a 
material that will completely absorb incident ultrasound with no reflections.  Also, for 
higher powers, the absorbed power might lead into heating up of the absorbing material 
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causing thermal expansion and thereby change in bouncy forces [12-15].  This might 
explain the difference of efficiency between low (100W) and high (150W) power 
application.  In fact, the speed of sound in Eq1 is also temperature dependent.  It could 
have been ideal to observe the water temperature at the same time during the experiment.  
However, this could have interfered with the force readings and complicate the 
experiment design.  For this reason, the c value during these experiments was assumed to 
be constant.  To minimize the thermal heating effect, a five-minute time break between 
the measurements was given.  It should also be noted that the calculated efficiency levels 
were not higher than pre-established limits i.e. (70-90%) eliminating the need for further 
investigation.  In this protocol, due to the design geometry of the force balance platform, 
the sonication coordinate was chosen as 170mm for limiting the energy density on the 
absorber in a way that compromises between the need to have the entire beam in the 
absorber and the damage that the focused ultrasound beam can do to the absorber.  The 
applied methodology has strengths for simplicity for conducting repeatability 
experiments in MR unit for MRgFUS application, and cost effectiveness. With radiation 
force methodology uncertainty in the measurements is also known to be lower when 
compared to hydrophone measurements where uncertainties could be up to 20% [9].  
 
The results showed that the TTS software was less efficient than the ExAblate 2100 
system by 3% for power values of 150 W.  However, the system did not exceed the 
established tolerance levels, and actually did not cause any excessive energy levels. Thus, 
in terms of safety, the TTS software proved to be safe.  This result might also imply that 
the TTS software might not be as efficient as the ExAblate 2100 CBS system in reaching 
high temperature values.  For this reason, it is very important to develop protocols for 
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measuring thermometry to observe if an efficient temperature increase for tumor ablation 
could be achieved by using TTS software as a next step.  
 
In the developed protocol, power values were only applied for 6 seconds, however, in 
practice longer sonication durations are used.  The force was calculated as time averaged 
value over a short-duration of time as 6 s, however, the main focus in the applied protocol 
was not the duration of the planned sonication but the power.  In fact, another protocol 
has been designed to test the deviation of sonication duration and any delay after 
sonication is stopped in case of emergency as a next step  
 
The developed protocol showed the importance of following the requirements of the 
quality management system ISO 13485 to improve the quality of the tests results in 
generating evidence when testing agreement of medical system before use in clinics. 
Results were convincing that the TTS software can deliver the power in a controlled way 
within expected efficiency limits.  Based on this evidence, novel protocols are designed 
for testing of remaining system parameters again following the requirements of ISO 
13485. 
e) Conclusions 
This study demonstrated the steps in evaluating the high risk TTS software; according to 
the international standard IEC 62304.  Acoustic power measurements proved to be 
consistent with the defined clinical standard.  However, the application of MRgFUS in 
the liver has some other important system parameters such as; sonication duration 
deviation, emergency stop delay, thermometry, and sonication position deviation that 
need to be quantified by applying reproducible protocols.  The next step in our work is 
to design novel protocols, check their feasibility, and improve these protocols for each of 
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these crucial system parameters.  The efficiency of power delivery is set as the first 
milestone, affecting all the other parameters.  For this reason, priority was given to 
measuring the efficiency of acoustic power delivery.  Based on this evidence, following 
the procedures of ISO13485, full validation of the system is planned.  This study is the 
first, but most crucial step in system validation as it paves the way to the next system 
parameters to be tested. 
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7) Legend of Figures and Tables  
Figure 1. Detailed description of hard- and software interfaces  
Figure 2 a. Weight scale and holder assembly as a moving target to place the weight 
scale on.  2b. Experimental Setup with membrane (ExAblate 2100 CBS, InSightec, 
Tirat Carmel, Israel.), wet tissue in between the membrane and the cylinder where 
degassed water is filled in. 2c. Weight scale holder assembly insertion. 2d. Positioning 
of weight scale and moving target using the tolerance between holder legs and the disk 
2e. Positioning of the scale during experiment to read the values 2f. Screen of the scale 
to read the values g) schematic view of the weight scale assembly, and side view with 
weight scale assembly inserted in degassed water in cylindrical water bath. 
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Figure 3a. Trans-Fusimo Execute Sonication Application showing the GUI for entering 
focus position, sonication duration and power for QA purposes, with buttons to start the 
transducer and execute the sonication b) CGA software of ExAblate 2100 (InSightec) 
system. 
Figure 4. Bland-Altman plot of difference in measured delivered acoustic power for 100 
W by TTS and ExAblate 2100 against the mean of the measured delivered acoustic 
power, by the first operator a) and second b), showing mean and mean±1.96SD as upper 
and lower limits of agreement, and for 150 W by TTS and ExAblate 2100 against the 
mean of the measured delivered acoustic power, by the first operator c) and second d), 
showing mean and mean±1.96SD as upper and lower limits of agreement 
Figure Appendix. Measured acoustic power for 1st   (a,b) and 2nd (c,d) operators by 
using TTS software and ExAblate 2100 software, with best fit trend line formula to 
calculate NRMSE. 
Table 1a) Test parameters which are logged into the GUI of TESA by the operators b) 
Descriptive statistics for electrical power values of 100W and calculated average 
efficiency c) Descriptive statistics for electrical power values of 150 W and calculated 
average efficiency.   
 
 
 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8) List of Table and Figures 
23 
 
 
 
 
 
 
  
24 
 
  
25 
 
 
 
 
 
 
  
 
26 
 
                     
 
 
 
 
 
 
 
 
 
 
